Home・Elenco Azioni・Editas Medicine Inc

Editas Medicine Inc

Chiusa

SettoreSettore sanitario

2.83 0.35

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2.7800000000000002

Massimo

2.89

Metriche Chiave
By Trading Economics
Entrata	6.8M -18M
Vendite	9.1M 12M
EPS	-0.15
Margine di Profitto	-153.322
Dipendenti	87
EBITDA	3.9M -20M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+183.69% upside

Dividendi
By Acuity
Utili prossimi	9 nov 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	25M 432M
Apertura precedente	2.48
Chiusura precedente	2.83

Notizie sul Sentiment di mercato

By Acuity

75%

25%

302 / 340 Classifica in Healthcare

Editas Medicine Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 ago 2026, 22:21 UTC

Editas Medicine Inc is trading lower in after-market hours, continuing a decline over the past four sessions amid broader concerns over consumer demand.

13 ago 2026, 21:32 UTC

Correlated Moves

Editas Medicine Inc advanced in after-hours trading, reflecting a shift in investor sentiment and aligning with a positive trend in the biotechnology sector.

12 ago 2026, 19:31 UTC

Editas Medicine Inc shares are lower today, continuing a decline since Tuesday. No specific news has been identified to explain the drop.

11 ago 2026, 19:46 UTC

Editas Medicine Inc shares are trading higher today, reflecting unusual strength. No specific company news was identified to explain this price action.

10 ago 2026, 23:26 UTC

Editas Medicine Inc shares are higher in after-market hours. No specific company news was identified to explain this movement amid broader market uncertainties.

7 ago 2026, 23:16 UTC

Editas Medicine Inc. shares were little changed in after-market trading, with no specific news identified. The stock remains above its 20-day moving average.

6 ago 2026, 23:02 UTC

Editas Medicine Inc shares are higher in after-market hours, reflecting positive momentum following a strong trading session despite no specific company news.

5 ago 2026, 22:02 UTC

News

Editas Medicine reports second-quarter loss of $18.2 million, better than expected. Shares are higher after positive updates on EDIT-401 program and revenue growth.

31 lug 2026, 19:56 UTC

Correlated Moves

EDIT shares lower amid broader biotech sector decline today.

30 lug 2026, 23:51 UTC

Editas Medicine Inc shares are lower in after-market trading, continuing a decline since Thursday's close while remaining near the lower end of its one-month range.

29 lug 2026, 23:46 UTC

Editas Medicine Inc shares are lower in after-market hours, with no specific news identified. The stock remains near its one-month low amid broader market caution.

28 lug 2026, 20:07 UTC

Editas Medicine Inc shares are trading lower today, continuing a broader trend in the biotechnology sector. The stock remains below its 20-day moving average.

27 lug 2026, 17:26 UTC

Editas Medicine Inc is trading higher today, following a notable peak. The upward movement comes amid easing inflation concerns from declining oil prices.

24 lug 2026, 17:46 UTC

Editas Medicine Inc shares are lower today, continuing a trend of declines over the past three sessions amid broader market volatility linked to falling oil prices.

22 lug 2026, 19:26 UTC

Editas Medicine Inc is lower today, continuing a decline since Tuesday's close. Broader market weakness may be influencing investor sentiment.

21 lug 2026, 23:11 UTC

Editas Medicine Inc shares are higher in after-market hours, reflecting positive momentum since Tuesday's close, though they remain below their 20-day moving average.

Confronto tra pari

Modifica del prezzo

Editas Medicine Inc Previsione

Obiettivo di Prezzo

By TipRanks

183.69% in crescita

Previsioni per 12 mesi

Media 8 USD 183.69%

Alto 15 USD

Basso 4 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Editas Medicine Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

6 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 6 che hanno fornito valutazioni azionarie a Editas Medicine Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

302 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.